FENNEC PHARMACEUTICALS INC's ticker is FENC and the CUSIP is 31447P100. A total of 17 filers reported holding FENNEC PHARMACEUTICALS INC in Q4 2017. The put-call ratio across all filers is - and the average weighting 0.4%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2021 | $1,349,000 | -54.1% | 217,295 | -45.0% | 0.03% | -56.1% |
Q4 2020 | $2,941,000 | +12.5% | 394,810 | -8.5% | 0.07% | -25.8% |
Q3 2020 | $2,615,000 | +27.6% | 431,470 | +75.8% | 0.09% | +20.3% |
Q2 2020 | $2,049,000 | +27.7% | 245,377 | -9.2% | 0.07% | -14.0% |
Q1 2020 | $1,605,000 | -35.9% | 270,209 | -30.0% | 0.09% | -25.2% |
Q4 2019 | $2,504,000 | +14.2% | 385,880 | -15.4% | 0.12% | -5.0% |
Q3 2019 | $2,193,000 | +24.9% | 455,979 | +3.8% | 0.12% | +39.1% |
Q2 2019 | $1,756,000 | -11.9% | 439,083 | +6.9% | 0.09% | -18.7% |
Q1 2019 | $1,993,000 | -14.4% | 410,932 | +12.6% | 0.11% | -35.2% |
Q4 2018 | $2,328,000 | +27.2% | 364,933 | +63.6% | 0.16% | +66.7% |
Q3 2018 | $1,830,000 | +207.6% | 223,123 | +291.4% | 0.10% | +175.0% |
Q2 2018 | $595,000 | +3.8% | 57,002 | +20.3% | 0.04% | -12.2% |
Q1 2018 | $573,000 | -3.2% | 47,376 | -19.8% | 0.04% | -12.8% |
Q4 2017 | $592,000 | +7.6% | 59,044 | +19.1% | 0.05% | +2.2% |
Q3 2017 | $550,000 | – | 49,593 | – | 0.05% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Opaleye Management Inc. | 900,000 | $5,742,000 | 2.14% |
Southpoint Capital Advisors LP | 3,997,214 | $25,502,000 | 1.23% |
Avoro Capital Advisors LLC | 1,105,999 | $7,056,000 | 0.42% |
683 Capital Management, LLC | 971,351 | $6,197,000 | 0.38% |
Eventide Asset Management | 720,000 | $4,594,000 | 0.20% |
Granahan Investment Management | 364,933 | $2,328,000 | 0.16% |
Zebra Capital Management LLC | 17,568 | $112,000 | 0.07% |
Hartford Financial Management Inc. | 10,000 | $64,000 | 0.02% |
Weiss Multi-Strategy Advisers LLC | 25,000 | $160,000 | 0.01% |
MEEDER ASSET MANAGEMENT INC | 9,740 | $62,000 | 0.01% |